LipoNova AG: Local Supervisory Agency Approves Production license of LipoNova’s Early-Stage Kidney Cancer Vaccine Reniale®   ***   LipoNova AG reaches key milestones in the Reniale development process during 2007. Costs below budget.   ***   LipoNova signs memorandum of understanding for the marketing of Reniale®   ***   
Our Business

Overview

LipoNova AG is a leading developer of effective therapies for non-metastatic renal cell carcinoma, a disease with a high unmet medical need. Almost two thirds of patients diagnosed with renal cell carcinoma have a life expectancy of less than five years.

Reniale®, our lead product, is the first autologous treatment with demonstrated efficacy and safety as an adjuvant therapy in non-metastatic disease.

LipoNova AG is well positioned to bring Reniale® to market and to expand its oncology franchise. Our leadership position, milestone accomplishments, phase III clinical trials and global network are helping us achieve our strategic development targets.